Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'MITOXANTRONE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 755 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Litman, T; Druley, TE; Stein, WD; Bates, SE
      From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance

      CELLULAR AND MOLECULAR LIFE SCIENCES
    2. Ferry, DM; van Zijl, PL; Wilson, WR
      Sensitive liquid chromatographic assay for the basic DNA intercalator (N,N-dimethylaminoethyl)-9-amino-5-methylacridine-4-carboxamide and its nitroarylmethyl quaternary prodrugs in biological samples

      JOURNAL OF CHROMATOGRAPHY B
    3. Galanina, O; Feofanov, A; Tuzikov, AB; Rapoport, E; Crocker, PR; Grichine, A; Egret-Charlier, M; Vigny, P; Le Pendu, J; Bovin, NV
      Fluorescent carbohydrate probes for cell lectins

      SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
    4. Erdem, A; Ozsoz, M
      Voltammetry of the anticancer drug mitoxantrone and DNA

      TURKISH JOURNAL OF CHEMISTRY
    5. Baitchev, G; Gorchev, G; Deliisky, T; Popovska, S; Raitcheva, T
      Perioperative locoregional application of mitoxantrone in patients with early breast carcinoma

      JOURNAL OF CHEMOTHERAPY
    6. Faivre, S; Raymond, E; Boige, V; Gatineau, M; Buthaut, X; Rixe, O; Bernareggi, A; Camboni, G; Armand, JP
      A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies

      CLINICAL CANCER RESEARCH
    7. Chisesi, T; Polistena, P; Contu, A; Coser, P; Indrizzi, L; Leoni, P; Majolino, I; Porcellini, A; Salvagno, L; Zambaldi, G; Rizzoli, V; Congiu, AM; Santini, G
      Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-Hodgkin's lymphoma: An effective and non toxic therapeutic alternative for adult and elderly patients

      LEUKEMIA & LYMPHOMA
    8. Gregory, SA; Vose, J; Modiano, M; Kraemer, K; Rifkin, R; Rubin, A; Menduni, T; Ghalie, R
      Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin- or mitoxantrone-containing regimen

      LEUKEMIA & LYMPHOMA
    9. van Loevezijn, A; Allen, JD; Schinkel, AH; Koomen, GJ
      Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    10. Thurnher, D; Kornfehl, J; Burian, M; Gedlicka, C; Selzer, E; Quint, C; Neuchrist, C; Kornek, GV
      Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck

      ANTI-CANCER DRUGS
    11. Small, EJ
      Docetaxel in prostate cancer

      ANTI-CANCER DRUGS
    12. Spath-Schwalbe, E
      Treatment of non-Hodgkin's lymphomas in the elderly

      ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE
    13. Niitsu, N; Iijima, K; Chizuka, A
      Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study

      ANNALS OF HEMATOLOGY
    14. Kern, W; Schleyer, E; Braess, J; Wittmer, E; Ohnesorge, J; Unterhalt, M; Wormann, B; Buchner, T; Hiddemann, W
      Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone [FIS-HAM] salvage therapy in highly resistant acuteleukemias

      ANNALS OF HEMATOLOGY
    15. Peters, FPJ; Lalisang, RI; Fickers, MMF; Erdkamp, FLG; Wils, JAJM; Houben, SGJ; Wals, J; Schouten, HC
      Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study

      ANNALS OF HEMATOLOGY
    16. Chester, JD; Clark, CJP; Gouldesbrough, DR; Bogle, SM; Bradley, CJ; Parker, D
      Management of lymphoma patients in a cancer unit: An audit of 15 years' experience in a district general hospital

      CLINICAL ONCOLOGY
    17. Kowalski, P; Wichert, A; Holm, PS; Dietel, M; Lage, H
      Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2

      CANCER GENE THERAPY
    18. Younes, A; Preti, HA; Hagemeister, FB; McLaughlin, P; Romaguera, JE; Rodriguez, MA; Samuels, BI; Palmer, JL; Cabanillas, F
      Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    19. Dowling, AJ; Panzarella, T; Ernst, DS; Neville, AJ; Moore, MJ; Tannock, IF
      A retrospective analysis of the relationship between changes in serum PSA,palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer

      ANNALS OF ONCOLOGY
    20. Alexopoulos, A; Kouroussis, C; Malamos, N; Kakolyris, S; Kalbakis, K; Kosmas, C; Mavroudis, D; Agelaki, S; Vlachonicolis, J; Sarra, E; Rigatos, G; Georgoulias, V
      Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study

      ANNALS OF ONCOLOGY
    21. Oudard, S; Caty, A; Humblet, Y; Beauduin, M; Suc, E; Piccart, M; Rolland, F; Fumoleau, P; Bugat, R; Houyau, P; Monnier, A; Sun, X; Montcuquet, P; Breza, J; Novak, J; Gil, T; Chopin, D
      Phase II study of vinorelbine in patients with androgen-independent prostate cancer

      ANNALS OF ONCOLOGY
    22. Borchmann, P; Schnell, R; Knippertz, R; Staak, JO; Camboni, GM; Bernareggi, A; Hubel, K; Staib, P; Schulz, A; Diehl, V; Engert, A
      Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    23. Kanzaki, A; Toi, M; Nakayama, K; Bando, H; Mutoh, M; Uchida, T; Fukumoto, M; Takebayashi, Y
      Expression of multidrug resistance-related transporters in human breast carcinoma

      JAPANESE JOURNAL OF CANCER RESEARCH
    24. Robak, T; Gora-Tybor, J; Lech-Maranda, E; Blonski, JZ; Robak, T
      Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies

      EUROPEAN JOURNAL OF HAEMATOLOGY
    25. Proctor, SJ; Taylor, PRA; Angus, B; Wood, K; Lennard, AL; Lucraft, H; Carey, PJ; Stark, A; Iqbal, A; Haynes, A; Russel, N; Leonard, RCF; Culligan, D; Conn, J; Jackson, GH
      High-dose ifosfamide in combination with etoposide and epirubicin (IVE) inthe treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy

      EUROPEAN JOURNAL OF HAEMATOLOGY
    26. Reiser, M; Bredenfeld, H; Engert, A; Diehl, V
      The role of ifosfamide in the treatment of relapsed and refractory lymphoma

      EUROPEAN JOURNAL OF HAEMATOLOGY
    27. Vogelzang, NJ
      Corticosteroids in advanced cancer - The Wooldridge/Anderson/Perry articlereviewed

      ONCOLOGY-NEW YORK
    28. Weiss, M
      Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    29. Seiter, K; Feldman, EJ; Sreekantaiah, C; Pozzuoli, M; Weisberger, J; Liu, D; Papageorgio, C; Weiss, M; Kancherla, R; Ahmed, T
      Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy

      LEUKEMIA
    30. Visani, G; Milligan, D; Leoni, F; Chang, J; Kelsey, S; Marcus, R; Powles, R; Schey, S; Covelli, A; Isidori, A; Litchman, M; Piccaluga, PP; Mayer, H; Malagola, M; Pfister, C
      Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

      LEUKEMIA
    31. Karp, JE
      MDR modulation in acute myelogenous leukemia: is it dead?

      LEUKEMIA
    32. Tarella, C; Zallio, F; Caracciolo, D; Cuttica, A; Corradini, P; Gavarotti, P; Ladetto, M; Podio, V; Sargiotto, A; Rossi, G; Gianni, AM; Pileri, A
      High-dose mitoxantrone plus melphalan (MITO/L-PAM) as conditioning regimensupported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity

      LEUKEMIA
    33. Robak, T; Blonski, JZ; Kasznicki, M; Gora-Tybor, J; Dwilewicz-Trojaczek, J; Boguradzki, P; Konopka, L; Ceglarek, B; Sulek, J; Kuliczkowski, K; Wolowiec, D; Stella-Holowiecka, B; Skotnicki, AB; Nowak, W; Moskwa-Sroka, B; Dmoszynska, A; Calbecka, M
      Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia

      LEUKEMIA
    34. Harvey, J; Cantrell, J; Campbell, M; Cartmell, A; Urba, W; Modiano, M; Schuster, M; Rubin, A; Newcomb, T; Ghalie, R
      Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer

      CANCER INVESTIGATION
    35. Rolak, LA
      Multiple sclerosis treatment 2001

      NEUROLOGIC CLINICS
    36. Savarese, DM; Halabi, S; Hars, V; Akerley, WL; Taplin, ME; Godley, PA; Hussain, A; Small, EJ; Vogelzang, NJ
      Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780

      JOURNAL OF CLINICAL ONCOLOGY
    37. Bonithon-Kopp, C; Milan, C; Chaplain, G; Sgro, C; Carli, PM
      Secondary leukemia after adjuvant chemotherapy for breast cancer - In reply

      JOURNAL OF CLINICAL ONCOLOGY
    38. Fossa, SD; Slee, PHT; Brausi, M; Horenblas, S; Hall, RR; Hetherington, JW; Aaronson, N; de Prijck, L; Collette, L
      Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group

      JOURNAL OF CLINICAL ONCOLOGY
    39. Lode, K; Fichtner, I; Kreuter, J; Berndt, A; Diederichs, JE; Reszka, R
      Influence of surface-modifying surfactants on the pharmacokinetic behaviorof C-14-poly (methylmethacrylate) nanoparticles in experimental tumor models

      PHARMACEUTICAL RESEARCH
    40. Chow, KU; Boehrer, S; Geduldig, K; Krapohl, A; Hoelzer, D; Mitrou, PS; Weidmann, E
      In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine

      HAEMATOLOGICA
    41. Dazzi, C; Cariello, A; Rosti, G; Tienghi, A; Molino, A; Sabbatini, R; Aieta, M; Frassineti, GL; Vertogen, B; Giovanis, P; Marangolo, M
      Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study

      HAEMATOLOGICA
    42. Santini, G; Nati, S; Spriano, M; Gallamini, A; Pierluigi, D; Congiu, AM; Truini, M; Rubagotti, A; Chisesi, T; Vimercati, R; Rossi, E; Sertoli, MR; Mattei, D; Marino, G; Gobbi, M
      Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma

      HAEMATOLOGICA
    43. Barone, S; Baer, MR; Sait, SNJ; Lawrence, D; Block, AW; Wetzler, M
      High-dose cytosine arabinoside and idarubicin treatment of chronic myeloidleukemia in myeloid blast crisis

      AMERICAN JOURNAL OF HEMATOLOGY
    44. Bennett, JM; Young, MS; Liesveld, JL; Paietta, E; Miller, KB; Lazarus, HM; Marsh, RD; Friedenberg, WR; Saba, HT; Hayes, FA; Dewald, GW; Hiddemann, W; Rowe, JM
      Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group study

      AMERICAN JOURNAL OF HEMATOLOGY
    45. Herman, EH; Zhang, J; Rifai, N; Lipshultz, SE; Hasinoff, BB; Chadwick, DP; Knapton, A; Chai, J; Ferrans, VJ
      The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin and mitoxantrone-induced cardiotoxicity

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    46. Caponigro, F; Avallone, A; Rivellini, F; Comella, P; Ionna, F; De Rosa, V; Comella, G
      Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    47. Alexiou, C; Arnold, W; Hulin, P; Klein, RJ; Renz, H; Parak, FG; Bergemann, C; Lubbe, AS
      Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting

      JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS
    48. Heidenreich, A; von Knobloch, R; Hofmann, R
      Current status of cytotoxic chemotherapy in hormone refractory prostate cancer

      EUROPEAN UROLOGY
    49. Creutzig, U; Berthold, F; Boos, J; Fleischhack, G; Gadner, H; Gnekow, A; Graubner, U; Henze, G; Hermann, J; Imbach, P; Jurgens, H; Kabisch, H; Korholz, D; Niemeyer, CM; Reinhardt, D; Reiter, A; Ritter, J; Spaar, HJ; Zimmermann, M
      Improved treatment results in children with AML: Results of study AML-BFM 93

      KLINISCHE PADIATRIE
    50. Willan, AR; O'Brien, BJ; Leyva, RA
      Cost-effectiveness analysis when the WTA is greater than the WTP

      STATISTICS IN MEDICINE
    51. Willan, AR; Lin, DY
      Incremental net benefit in randomized clinical trials

      STATISTICS IN MEDICINE
    52. Ron, IG; Wigler, N; Borovik, R; Brufman, G; Rizel, S; Shani, A; Brenner, J; Farbstein, H; Dale, A; Inbar, MJ; Brenner, HJ; Chaitchik, S; Catane, R
      CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer - A phase III randomized multicenter study

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    53. Lichtman, SM; Kolitz, J; Budman, DR; Schulman, P; Vinciguerra, V; Hoffman, M; Mittelman, A; Allen, SL; Fusco, D; Hayes, FA
      Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, novantrone (mitoxantrone), vincristine, prednisone (TNOP)

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    54. Kalaycio, M; Pohlman, B; Elson, P; Lichtin, A; Hussein, M; Tripp, B; Andresen, S
      Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    55. Hu, JB; Shang, J; Li, QL
      Electrochemical studies of mitoxantrone interaction with DNA at a Ni/GC ion implantation modified electrode

      CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE
    56. Hu, JB; Li, QL
      Studies on the voltammetric behavior of mitoxantrone and its application at the Ni/GC modified electrode

      CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE
    57. Willan, AR
      Analysis, sample size, and fewer for estimating incremental net health benefit from clinical trial data

      CONTROLLED CLINICAL TRIALS
    58. Frank, C; Zierhut, D; Schulz-Ertner, I; Wannenmacher, M
      Centroblastic-centrocytic non-Hodgkin's lymphoma stage I-III: Patterns of failure following radiotherapy

      STRAHLENTHERAPIE UND ONKOLOGIE
    59. Kiba, T; Numata, K; Kitamura, T; Morita, K; Saito, S; Sekihara, H
      Combination therapy of percutaneous mitoxantrone injection, percutaneous ethanol injection, and transcatheter arterial embolization for intrahepatic hepatocellular carcinoma and adrenal metastasis

      HEPATO-GASTROENTEROLOGY
    60. Boiardi, A; Eoli, M; Salmaggi, A; Zappacosta, B; Fariselli, L; Milanesi, I; Broggi, G; Silvani, A
      Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours

      JOURNAL OF NEURO-ONCOLOGY
    61. Bahng, H; Lee, JH; Ahn, JH; Lee, JH; Lee, JS; Kim, SH; Kim, WK; Lee, KH
      Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia

      LEUKEMIA RESEARCH
    62. Feldman, EJ
      Commentary: dose intensive chemotherapy in acute myeloid leukemia

      LEUKEMIA RESEARCH
    63. Bouhadir, KH; Alsberg, E; Mooney, DJ
      Hydrogels for combination delivery of antineoplastic agents

      BIOMATERIALS
    64. Loeb, DM; Bowers, DC; Civin, CI; Friedman, AD
      Intensive timed sequential remission induction chemotherapy with high-dosecytarabine for childhood acute myeloid leukemia

      MEDICAL AND PEDIATRIC ONCOLOGY
    65. Copur, MS; Ledakis, P; Lynch, J; Hauke, R; Tarantolo, S; Bolton, M; Norvell, M; Muhvic, J; Hake, L; Wendt, J
      Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer

      SEMINARS IN ONCOLOGY
    66. Taplin, ME; Bubley, GJ; Rajeshkumar, B; Shuster, T; Ko, YJ; Morganstern, DE
      Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer

      SEMINARS IN ONCOLOGY
    67. Oh, WK; George, DJ; Kaufman, DS; Moss, K; Smith, MR; Richie, JP; Kantoff, PW
      Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report

      SEMINARS IN ONCOLOGY
    68. Ryan, CW; Stadler, WM; Vogelzang, NJ
      Docetaxel and exisulind in hormone-refractory prostate cancer

      SEMINARS IN ONCOLOGY
    69. Tolcher, AW
      Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer

      SEMINARS IN ONCOLOGY
    70. Keefe, DL
      Anthracycline-induced cardiomyopathy

      SEMINARS IN ONCOLOGY
    71. Smith, PJ; Wiltshire, M
      Cytometry of antitumor drug-intracellular target interactions

      METHODS IN CELL BIOLOGY, VOL 64
    72. Joshi, AS; Pieniaszek, HJ; Vokes, EE; Vogelzang, NJ; Davidson, AF; Richards, LE; Chai, MF; Finizio, M; Ratain, MJ
      Elimination pathways of [C-14]losoxantrone in four cancer patients

      DRUG METABOLISM AND DISPOSITION
    73. Makhija, S; Leitao, M; Sabbatini, P; Bellin, N; Almadrones, L; Leon, L; Spriggs, DR; Barakat, R
      Complications associated with intraperitoneal chemotherapy catheters

      GYNECOLOGIC ONCOLOGY
    74. Nicoletto, MO; Artioli, G; Donach, M; Sileni, VC; Monfardini, S; Talamini, R; Veronesi, A; Ferrazzi, E; Tumolo, S; Visona, E; Amichetti, M; Endrizzi, L; Salvagno, L; Prosperi, A; Azzoni, P
      Elderly ovarian cancer: Treatment with mitoxantrone-carboplatin

      GYNECOLOGIC ONCOLOGY
    75. Kucuk, O; Fisher, E; Moinpour, CM; Coleman, D; Hussain, MHA; Sartor, AO; Chatta, GS; Lowe, BA; Eisenberger, MA; Crawford, ED
      Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group Study (SWOG 9235)

      UROLOGY
    76. Hiddemann, W; Buchner, T
      Current status and perspectives of therapy for acute myeloid leukemia

      SEMINARS IN HEMATOLOGY
    77. Edan, G
      Treatment of rapidly worsening multiple sclerosis

      REVUE NEUROLOGIQUE
    78. Grichine, A; Feofanov, A; Karmakova, T; Kazachkina, N; Pecherskih, E; Yakubovskaya, R; Mironov, A; Egret-Charlier, M; Vigny, P
      Influence of the substitution of 3-vinyl by 3-formyl group on the photodynamic properties of chlorin P6: Molecular, cellular and in vivo studies

      PHOTOCHEMISTRY AND PHOTOBIOLOGY
    79. Mancardi, GL; Saccardi, R; Filippi, M; Gualandi, F; Murialdo, A; Inglese, M; Marrosu, MG; Meucci, G; Massacesi, L; Lugaresi, A; Pagliai, F; Sormani, MP; Sardanelli, F; Marmont, A
      Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS

      NEUROLOGY
    80. Robak, T; Gora-Tybor, J
      Cladribine combined with mitoxantrone in the treatment of blastic phase ofchronic myeloid leukemia

      NEOPLASMA
    81. Sissi, C; Moro, S; Richter, S; Gatto, B; Menta, E; Spinelli, S; Krapcho, AP; Zunino, F; Palumbo, M
      DNA-interactive anticancer aza-anthrapyrazoles: Biophysical and biochemical studies relevant to the mechanism of action

      MOLECULAR PHARMACOLOGY
    82. Heidenreich, A; Hofmann, R; Engelmann, UH
      The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer

      JOURNAL OF UROLOGY
    83. Bryant, J; Clegg, A; Milne, R
      Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    84. Uchida, N; Fujisaki, T; Eaves, AC; Eaves, CJ
      Transplantable hematopoietic stem cells in human fetal liver have a CD34(+) side population (SP) phenotype

      JOURNAL OF CLINICAL INVESTIGATION
    85. Gaponenko, SV; Gaiduk, AA; Kulakovich, OS; Maskevich, SA; Strekal, ND; Prokhorov, OA; Shelekhina, VM
      Raman scattering enhancement using crystallographic surface of a colloidalcrystal

      JETP LETTERS
    86. Siva, AC; Raval-Fernandes, S; Stephen, AG; La Femina, MJ; Scheper, RJ; Kickhoefer, VA; Rome, LH
      Up-regulation of vaults may be necessary but not sufficient for multidrug resistance

      INTERNATIONAL JOURNAL OF CANCER
    87. Lage, H; Perlitz, C; Abele, R; Tampe, R; Dietel, M; Schadendorf, D; Sinha, P
      Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone

      FEBS LETTERS
    88. Sallach, S; Schmidt, T; Pehl, C; Gallenberger, S; Keiditsch, E; Starostik, P; Ott, G; Schepp, W
      Primary low-grade B cell non-Hodgkin's lymphoma of MALT type simultaneously arising in the colon and in the lung - Report of a case

      DISEASES OF THE COLON & RECTUM
    89. Maliepaard, M; Scheffer, GL; Faneyte, IF; van Gastelen, MA; Pijnenborg, ACLM; Schinkel, AH; van de Vijver, MJ; Scheper, RJ; Schellens, JHM
      Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues

      CANCER RESEARCH
    90. Komatani, H; Kotani, H; Hara, Y; Nakagawa, R; Matsumoto, M; Arakawa, H; Nishimura, S
      Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure

      CANCER RESEARCH
    91. Honjo, Y; Hrycyna, CA; Yan, QW; Medina-Perez, WY; Robey, RW; van de Laar, A; Litman, T; Dean, M; Bates, SE
      Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells

      CANCER RESEARCH
    92. DiPaola, RS; Chenven, ES; Shih, WJ; Lin, Y; Amenta, P; Goodin, S; Shumate, A; Capanna, T; Cardiella, M; Cummings, KB; Aisner, J; Todd, MB
      Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma

      CANCER
    93. Papadimitriou, CA; Kouroussis, C; Moulopoulos, LA; Vlahos, G; Rodolakis, A; Kiamouris, C; Diakomanolis, E; Gika, D; Michalas, S; Dimopoulos, MA
      Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer

      CANCER
    94. Perez-Gracia, JL; Colomer, R; Esteban, E; Barcelo, R; Benavides, M; Puertas, J; Arcediano, A; Tornamira, MV; Valentin, V; Munoz, A; Cortes-Funes, H; Hornedo, J
      High-Dose Mitoxantrone and Cyclophosphamide Without Stem Cell Support in Patients with High-Risk and Advanced Breast Carcinoma - A Phase II Multicentric Trial

      CANCER
    95. Sherman, EJ; Pfister, DG; Ruchlin, HS; Rubin, DM; Radzyner, MH; Kelleher, GH; Slovin, SF; Kelly, WK; Scher, HI
      The collection of indirect and nonmedical direct costs (COIN) form - A newtool for collecting the invisible costs of androgen independent prostate carcinoma

      CANCER
    96. Ferrari, AC; Chachoua, A; Singh, H; Rosenthal, M; Taneja, S; Bednar, M; Mandeli, J; Muggia, F
      A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma

      CANCER
    97. Zhou, Z; Zwelling, LA; Ganapathi, R; Kleinerman, ES
      Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II alpha gene transfer is independent of topoisomerase II beta

      BRITISH JOURNAL OF CANCER
    98. Miyake, H; Hara, S; Arakawa, S; Kamidono, S; Hara, I
      Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model

      BRITISH JOURNAL OF CANCER
    99. Somlo, G; Doroshow, JH; Synold, T; Longmate, J; Reardon, D; Chow, W; Forman, SJ; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Shibata, SI; Tetef, ML; Yen, Y; Kogut, N; Schriber, J; Alvarnas, J
      High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome

      BRITISH JOURNAL OF CANCER
    100. Hazlehurst, LA; Valkov, N; Wisner, L; Storey, JA; Boulware, D; Sullivan, DM; Dalton, WS
      Reduction in drug-induced DNA double-strand breaks associated with beta 1 integrin-mediated adhesion correlates with drug resistance in U937 cells

      BLOOD


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/05/20 alle ore 14:20:26